Skip to main content

Medications for Tenosynovial Giant Cell Tumor

Other names: GCTTS; Giant Cell Tumor of the Tendon Sheath; Nodular Tenosynovitis; TGCT; TSGCT

Medically reviewed by Carmen Pope, BPharm. Last updated on Jun 19, 2025.

Tenosynovial giant cell tumor (TGCT) is a non-cancerous growth that forms in the soft tissue around small or large joints causing pain, swelling and movement issues.

The parts within the joints that are affected include the tendon sheath (membrane that covers the tendon),  the bursae (fluid-filled sacs that form a cushion between bones, tendons and muscles) and the synovial membrane (a thin membrane that is the inner layer of the joint capsule).

The growth of the tumor damages and disrupts the surrounding structures and tissues causing the pain, stiffness and reduced joint motility. If the tumor is left untreated or recurs after treatment the damage can cause significant joint issues and disability.

Surgery is the primary treatment, but medical therapy is used for inoperable or recurrent cases. Medications used include:

  • CSF-1 Receptor Inhibitors (Tyrosine Kinase Inhibitors): Pexidartinib (Turalio) and  vimseltinib (Romvimza).

Drugs used to treat Tenosynovial Giant Cell Tumor

The medications listed below are related to or used in the treatment of this condition.

Drug name Rating Reviews Activity ? Rx/OTC Pregnancy CSA Alcohol
Turalio Rate Add review Rx N X
Generic name:
pexidartinib systemic
Drug class:
multikinase inhibitors
For consumers:
dosage, interactions, side effects
For professionals:
Prescribing Information
pexidartinib 8.0 1 review for pexidartinib to treat Tenosynovial Giant Cell Tumor Rx N X
Generic name:
pexidartinib systemic
Brand name:
Turalio
Drug class:
multikinase inhibitors
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph
Romvimza Rate Add review Rx N
Generic name:
vimseltinib systemic
Drug class:
miscellaneous antineoplastics
For consumers:
dosage, interactions, side effects
For professionals:
Prescribing Information
vimseltinib Rate Add review Rx N
Generic name:
vimseltinib systemic
Brand name:
Romvimza
Drug class:
miscellaneous antineoplastics
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph

Legend

Rating For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective).
Activity Activity is based on recent site visitor activity relative to other medications in the list.
Rx Prescription only.
OTC Over-the-counter.
Rx/OTC Prescription or Over-the-counter.
Off-label This medication may not be approved by the FDA for the treatment of this condition.
EUA An Emergency Use Authorization (EUA) allows the FDA to authorize unapproved medical products or unapproved uses of approved medical products to be used in a declared public health emergency when there are no adequate, approved, and available alternatives.
Expanded Access Expanded Access is a potential pathway for a patient with a serious or immediately life-threatening disease or condition to gain access to an investigational medical product (drug, biologic, or medical device) for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available.
Pregnancy Category
A Adequate and well-controlled studies have failed to demonstrate a risk to the fetus in the first trimester of pregnancy (and there is no evidence of risk in later trimesters).
B Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.
C Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use in pregnant women despite potential risks.
D There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use in pregnant women despite potential risks.
X Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use in pregnant women clearly outweigh potential benefits.
N FDA has not classified the drug.
Controlled Substances Act (CSA) Schedule
M The drug has multiple schedules. The schedule may depend on the exact dosage form or strength of the medication.
U CSA Schedule is unknown.
N Is not subject to the Controlled Substances Act.
1 Has a high potential for abuse. Has no currently accepted medical use in treatment in the United States. There is a lack of accepted safety for use under medical supervision.
2 Has a high potential for abuse. Has a currently accepted medical use in treatment in the United States or a currently accepted medical use with severe restrictions. Abuse may lead to severe psychological or physical dependence.
3 Has a potential for abuse less than those in schedules 1 and 2. Has a currently accepted medical use in treatment in the United States. Abuse may lead to moderate or low physical dependence or high psychological dependence.
4 Has a low potential for abuse relative to those in schedule 3. It has a currently accepted medical use in treatment in the United States. Abuse may lead to limited physical dependence or psychological dependence relative to those in schedule 3.
5 Has a low potential for abuse relative to those in schedule 4. Has a currently accepted medical use in treatment in the United States. Abuse may lead to limited physical dependence or psychological dependence relative to those in schedule 4.
Alcohol
X Interacts with Alcohol.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.